A Review of Analytical Methods for Determination of Pravastatin in Pharmaceutical Dosage Forms and Biological Fluids
Abstract
Pravastatin is an inhibitor of HMG-CoA reductase inhibitor which is used as a hypolipidemic agent to reduce cholesterol level. Chemically, 9-Fluoro-11β,17-dihydroxy-16α-methyl-3,20-dioxopregna-1,4-dien-21-yl disodium phosphate. Pravastatin is a drug of choice for the cardiovascular disease. It reduces the coronary and cerebrovascular morbidity and mortality in middle aged individual. Elevated plasma concentration of C-reactive protein are associated with protein increased cardiovascular disease, long term therapy with pravastatin an agent that reduces cardiovascular risk, might alter levels of this inflammatory parameter. This review consist of various analytical methods for the determination of pravastatin in various marketed pharmaceutical formulation of biological fluid. Analytical methods consist of various chromatographic methods, spectrophotometer methods and electrical methods reported for determination of pravastatin.
References
2. Corrie PG, Pippa G. (2008). "Cytotoxic chemotherapy: clinical aspects". Medicine 36 (1): 24–28. doi:10.1016/j.mpmed.2007.10.012.
3. cancer.gov/drugdictionary?CdrID=42674
4. Danshiitsoodol N, de Pinho CA, Matoba Y, Kumagai T, Sugiyama M (2006). "The mitomycin C (MMC)-binding protein from MMC-producing microorganisms protects from the lethal effect of bleomycin: crystallographic analysis to elucidate the binding mode of the antibiotic to the protein". J Molec Biol 360 (2): 398–408. doi:10.1016/j.jmb.2006.05.017. PMID 16756991.
5. Cummings J et al. Eur J Cancer 1995; 31A: 1928-33
6. 1657.A to Z Drug Facts (A to Z Drug Facts, 4th ed) by David S. Tatro and Facts and Comparisons
